Predictive value of preoperative serum CCL2, CCL18, and VEGF for the patients with gastric cancer

Jianghong Wu,Xiaowen Liu,Yanong Wang

doi:10.1186/1472-6890-13-15

Abstract

BackgroundTo investigate the expression of chemokine ligand 2 (CCL2), chemokine ligand 18 (CCL18), and vascular endothelial growth factor (VEGF) in peripheral blood of patients with gastric cancer and their correlation with presence of malignancy and disease progression.MethodsSixty patients with pathological proved gastric cancer were prospectively included into study. The levels of CCL2, CCL18, and VEGF in peripheral blood were examined by enzyme-linked immunosorbentassay (ELISA). Peripheral blood from 20 healthy people was examined as control.ResultsThe preoperative serum levels of CCL2, CCL18 and VEGF in gastric cancer patients were significantly higher than that of controls (P <0.001, P <0.001, and P <0.001, respectively). ROC curve analysis showed that with a cut-off value of ≥1272.8, the VEGF*CCL2 predicted the presence of gastric cancer with 83% sensitivity and 80% specificity. Preoperative serum CCL2 was significantly correlated to N stage (P =0.040); CCL18 associated with N stage (P =0.002), and TNM stage (P =0.002); VEGF correlated to T stage (P =0.000), N stage (P =0.015), and TNM stage (P =0.000).ConclusionPreoperative serum levels of CCL2 and VEGF could play a crucial role in predicting the presence and progression of gastric cancer.

Highlights

To investigate the expression of chemokine ligand 2 (CCL2), chemokine ligand 18 (CCL18), and vascular endothelial growth factor (VEGF) in peripheral blood of patients with gastric cancer and their correlation with presence of malignancy and disease progression
The aim of this study was to investigate the relationship between the preoperative serum levels of CCL2, CCL18, and VEGF, and the clinicopathological factors in patients with gastric cancer
We measured the concentration of CCL2, CCL18, and VEGF in a series of 60 serum samples from gastric cancer

Summary

Introduction

To investigate the expression of chemokine ligand 2 (CCL2), chemokine ligand 18 (CCL18), and vascular endothelial growth factor (VEGF) in peripheral blood of patients with gastric cancer and their correlation with presence of malignancy and disease progression. Some serum tumor markers such as AFP, CEA, CA19-9, CA72-4, and CA50 were currently the best clinical markers for gastric cancer. They were no good diagnostic tumor makers in early stage gastric cancer. The CCL chemokines represented the largest family of chemokines. They could attract monocytes, macrophages, T cells, B cells, eosinophils, dendritic cells, mast cells and natural killer cells [3]. CCL18 was a newly defined member of C-C subgroup of chemokines. It played an important role in inflammation and generation of the immune response. The involvement of CCL18 in cancer was not clear

Objectives

Methods

Results

Conclusion